Additionally, the high-risk group demonstrated resistance to several therapeutic agents, including CDK9, cytarabine, docetaxel, epirubicin, mitoxantrone, Obatoclax Mesylate, rapamycin, vincristine, and its synthetic analogues, highlighting the potential of the autophagy prognostic model in predicting treatment resistance in multiple myeloma (MM). Here, CDK9 is linked to Miyoshi myopathy.